Targeting CXCR1/2 Does Not Improve Insulin Secretion After Pancreatic Islet Transplantation: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial in Type 1 Diabetes | Zendy

Paola Maffi | Zendy; Torbjörn Lundgren | Zendy; Gunnar Tufveson | Zendy; Ehab Rafael | Zendy; James Shaw | Zendy; Aaron Liew | Zendy; F Saudek | Zendy; Piotr Witkowski | Zendy; Karolina Gołąb | Zendy; Federico Bertuzzi | Zendy; Bengt Gustafsson | Zendy; L. Daffonchio | Zendy; Pier Adelchi Ruffini | Zendy; Lorenzo Piemonti | Zendy; Rita Nano | Zendy; Alessia Mercalli | Zendy; Vito Lampasona | Zendy; Paola Magistretti | Zendy; Valeria Sordi | Zendy; Antonio Secchi | Zendy; Barbara Antonioli | Zendy; Marta Galuzzi | Zendy; Marta Cecilia Tosca | Zendy; Luciano De Carlis | Zendy; Giacomo Colussi | Zendy; Olle Korsgren | Zendy; Helena Pollard | Zendy

Open Access

Targeting CXCR1/2 Does Not Improve Insulin Secretion After Pancreatic Islet Transplantation: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial in Type 1 Diabetes

Author(s) -

Paola Maffi,

Torbjörn Lundgren,

Gunnar Tufveson,

Ehab Rafael,

James Shaw,

Aaron Liew,

F Saudek,

Piotr Witkowski,

Karolina Gołąb,

Federico Bertuzzi,

Bengt Gustafsson,

L. Daffonchio,

Pier Adelchi Ruffini,

Lorenzo Piemonti,

Rita Nano,

Alessia Mercalli,

Vito Lampasona,

Paola Magistretti,

Valeria Sordi,

Antonio Secchi,

Barbara Antonioli,

Marta Galuzzi,

Marta Cecilia Tosca,

Luciano De Carlis,

Giacomo Colussi,

Olle Korsgren,

Helena Pollard

Publication year - 2020

Publication title -

diabetes care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.636

H-Index - 363

eISSN - 1935-5548

pISSN - 0149-5992

DOI - 10.2337/dc19-1480

Subject(s) - medicine , double blind , placebo , diabetes mellitus , type 2 diabetes , islet , randomized controlled trial , transplantation , insulin , endocrinology , gastroenterology , pathology , alternative medicine

Reparixin is an inhibitor of CXCR1/2 chemokine receptor shown to be an effective anti-inflammatory adjuvant in a pilot clinical trial in allotransplant recipients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research